Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Peripheral Arterial DiseaseDiabetic Foot
Interventions
BIOLOGICAL

3 x 10^6 cells

3 x 10\^6 cells administered on Study Days 1 and 8

BIOLOGICAL

10 x 10^6 cells

10 x 10\^6 cells administered on Study Days 1 and 8

BIOLOGICAL

30 x 10^6 cells

30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8

BIOLOGICAL

100 x 10^6 cells

100 x 10\^6 cells administered on Study Days 1 and 8

Trial Locations (11)

27599

University of North Carolina School of Medicine, Chapel Hill

53792

University of Wisconsin, Madison

60064

Dr. Wiliam M. Scholl College of Podiatric Medicine, North Chicago

62702

Southern Illinois University School of Medicine, Springfield

73104

University of Oklahoma Health Sciences Center, Oklahoma City

78229

Endeavor Clinical Trials PA, San Antonio

85012

Carl T. Hayden Veterans Affairs Medical Center, Phoenix

90095

UCLA, Los Angeles

94305-5317

Stanford University School of Medicine, Stanford

78501-2930

Complete Family Foot Care - McAllen Office, McAllen

22908-0709

University of Virginia, Charlottesville

All Listed Sponsors
lead

Celularity Incorporated

INDUSTRY

NCT01859117 - Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU | Biotech Hunter | Biotech Hunter